NCT04284319

Brief Summary

Normothermic regional perfusion (NRP) utilizes Extracorporeal Membrane Oxygenation (ECMO) or cardiopulmonary bypass to reperfuse the heart and other organs in situ after isolation and ligation of the cerebral vessels. In situ resuscitation of the heart has the added advantage of allowing full hemodynamic and echocardiographic assessment of the donor heart prior to final acceptance for transplantation without the imminent danger of ongoing warm ischemia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable heart-failure

Timeline
Completed

Started Jan 2020

Typical duration for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 20, 2020

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

January 24, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 25, 2020

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2022

Completed
Last Updated

February 13, 2023

Status Verified

February 1, 2023

Enrollment Period

2.9 years

First QC Date

January 24, 2020

Last Update Submit

February 10, 2023

Conditions

Keywords

Heart TransplantationNormothermic Regional PerfusionNRPDonation After Circulatory DeathDCD

Outcome Measures

Primary Outcomes (1)

  • Successful NRP-DCD Heart transplants

    The primary outcome is the rate of successful NRP-DCD heart transplants.

    One Year

Secondary Outcomes (4)

  • Number of living authorized representatives who authorize candidate's organs for donation and research

    One Year

  • Number of candidates who are transferred to NYU Langone Health for donation after circulatory death (DCD)

    One Year

  • Number of candidates who progress to death after withdrawal of care

    One Year

  • Number of Donors whose hearts are deemed suitable for donation following normothermic regional perfusion (NRP)

    One Year

Study Arms (1)

DCD Heart Transplantation Using NRP

EXPERIMENTAL

Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)

Procedure: DCD Heart Transplantation Using NRP

Interventions

Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)

DCD Heart Transplantation Using NRP

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Recipient is ≥ 18 years old
  • Recipient, or their designated healthcare proxy, is able and willing to sign informed consent
  • Recipient meets standard listing criteria for heart transplantation at NYU Langone Health Transplant Institute

You may not qualify if:

  • Recipient is \< 18 years old
  • Recipient, or their designated healthcare proxy, is unable to sign informed consent
  • Recipient is participating in another interventional trial
  • Recipient has a known history of HIV infection
  • Recipient has any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Nader Moazami, MD

    NYU Langone

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Pilot Study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 24, 2020

First Posted

February 25, 2020

Study Start

January 20, 2020

Primary Completion

November 30, 2022

Study Completion

November 30, 2022

Last Updated

February 13, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations